Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 7, 2016, Pages 738-746

  Lutchman, G ^a   Nguyen, N H ^b   Chang, C Y ^a   Ahmed, A ^a   Daugherty, T ^a   Garcia, G ^a   Kumari, R ^a   Gupta, S ^c   Doshi, D ^c   Nguyen, M H ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; CYCLOSPORIN; HEMOGLOBIN; INTERFERON; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; ANTIVIRUS AGENT;

ADULT; ARTHRALGIA; ARTICLE; CAUCASIAN; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DECREASED APPETITE; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HISPANIC; HUMAN; HYPERTENSION; INSOMNIA; INTENTION TO TREAT ANALYSIS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PHOTOSENSITIVITY; POSTOPERATIVE PERIOD; PREDICTOR VARIABLE; PRIORITY JOURNAL; PRURITUS; RASH; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; AGED; GENETICS; GENOTYPE; HEPACIVIRUS; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIMEPREVIR; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 84991380573     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13761     Document Type: Article

References (28)

1. Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26(3 Suppl. 1): 21S–8S.
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36(5 Suppl. 1): S35–46.
3. Biggins SW, Bambha KM, Terrault NA, et al. Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl 2012; 18: 1471–8.
4. Kuo A, Terrault NA. Management of hepatitis C in liver transplant recipients. Am J Transplant 2006; 6: 449–58.
5. Kitchens WH, Yeh H, Markmann JF. Hepatic retransplant: what have we learned? Clin Liver Dis 2014; 18: 731–51.
6. Yu ML, Lin S-M, Chuang W-L, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006; 11: 985–94.
7. Trapero-Marugán M, Mendoza J, Chaparro M, et al. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. World J Gastroenterol 2011; 17: 493–8.
8. Metts J, Carmichael L, Kokor W, Scharffenberg R. Hepatitis C: liver transplantation. FP Essent 2014; 427: 25–31.
9. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889–98.
10. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375–82.
11. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756–65.
12. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405–16.
13. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006; 12: 1192–204.
14. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827–38.
15. Aqel BA, Pungpapong S, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology 2015; 62: 1004–12.
16. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483–93.
17. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649–59.
18. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–2.
19. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82.
20. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705–16.
21. Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a Phase 3 study (OPTIMIST-2). Hepatology 2015; 64: 360–9.
22. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther 2015; 42: 559–73.
23. Shiffman ML, James AM, Long AG, Alexander PC. Treatment of Chronic HCV With Sofosbuvir and Simeprevir in Patients With Cirrhosis and Contraindications to Interferon and/or Ribavirin. Am J Gastroenterol 2015; 110: 1179–85.
24. Pungpapong S, Aqel B, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015; 61: 1880–6.
25. Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol 2007; 102: 1383–91.
26. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867–77.
27. Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 2016; 150: 419–29.
28. Saxena V, Manos MM, Yee HS, et al. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther 2014; 39: 1213–24.